Item 2.02 Results of Operations and Financial Condition. On March 26, 2026 Quoin Pharmaceuticals Ltd. (the “Company”) announced its fourth quarter and fiscal year 2025 financial results. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information set forth and incorporated by reference in this Item 2.02 shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and the Company does not incorporate it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
QNRX Quoin Pharmaceuticals, Ltd. - 8-K
Accession
0001104659-26-0349512.029.01
Item 2.02 - Results of Operations and Financial Condition
Earnings press release item. The actual results are typically in Exhibit 99.1 - fetch may not have completed.
Item 9.01 - Financial Statements and Exhibits
30 words
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated March 26, 2026 104 Cover Page Interactive Data file (embedded within the Inline XBRL document)